Research & Development
Policy & Regulation
Trends & Finance
Nasdaq issues delisting notice to T2 Biosystems
T2 Biosystems has received a delisting notice from Nasdaq after failing to satisfy the minimum $35 million market value of listed securities threshold required to remain listed.
November 27, 2023
Invitae receives noncompliance notice from NYSE
San Francisco-based medical genetics company Invitae received a notice of noncompliance from the New York Stock Exchange (NYSE) on September 20 for its stock price closing under $1.00 per share for 30 consecutive days.
September 25, 2023
Report: Lack of standardization a ‘huge’ issue during pandemic, problems persist
A lack of standardization of infectious disease consumables was “a huge, unanticipated issue during the pandemic” that still needs to be resolved, according to a report in GenomeWeb.
September 15, 2023
Precipio prices $2M stock offering and concurrent private placement
The specialty cancer diagnostics company intends to use the net proceeds for working capital and general corporate purposes.
June 8, 2023
Trinity Biotech receives minimum-bid notice from Nasdaq
In accordance with the Nasdaq listing rule in question, Trinity has 180 calendar days, or until October 16, to regain compliance with the minimum bid price requirement.
April 25, 2023
Lucira Health files for bankruptcy despite receiving FDA green light
The firm is seeking a strategic or financial partner for the resumption of manufacturing and development of additional home diagnostic testing products.
February 27, 2023
OpGen closes $7.5 million public offering
OpGen closed a public offering of an aggregate of 2.6 million shares of its common stock, Series A-1 warrants, to purchase the same amount of common stock and Series A-2 warrants at a combined public offering price of $2.90 per share.
January 17, 2023
OpGen announces one-for-20 reverse stock split
The reverse stock split, approved by its stockholders at a special meeting on November 30, has been implemented to increase the firm's share price so that it could regain compliance with Nasdaq’s minimum bid price listing requirement.
January 5, 2023
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
BioAffinity's CyPath Lung lab-developed test uses flow cytometry and machine-learning algorithms to profile the approximately 20 million cells in an average sputum sample in less than 20 minutes.
December 19, 2022
Prometheus Biosciences announces $500M stock offering
The San Diego-based biotech company is taking a precision medicine approach for the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.
December 12, 2022
Blood volume diagnostic firm Daxor closes $2.1M offering of common stock
The New York firm plans to use the net proceeds to develop its products, fund capital expenditures, or invest in or acquire other businesses, among other potential uses.
November 17, 2022
Genetron Health receives minimum-bid share price notification from Nasdaq
The company said it has 180 days, or until April 26, 2023, to regain compliance under the Nasdaq listing rules.
November 7, 2022
Page 1 of 3